RE: H.C. Wainwright analyst Andrew Fein please expalin..:)That's the problem, there was no reason and I mean no reason other than the main rival MK-7264 having greater efficacy (which was well know and understood, article even on bb) with cough frequency (PRE TRIAL) which would lead anyone to believe that BLU 5937 has the same potency at relevant dosage as a placebo for cough frequency. This finding is actually far worse than 2016 as this has effectively written BLU 5937 off, for something that was virtually 100% similar to rivals pre-test - especially as BLU is more effective (far more so relatively speaking) than rivals for taste loss. That is why it is so profoundly shocking (and pretty disgusting actually) especially at phase 2. The chances of it happening would be remote in the extreme, that's why I think this whole thing stinks to high heaven.